(Q36791108)

16 August 2017

1 reference

title

Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature (English)

1 reference

nephrogenic systemic fibrosis

16 August 2017

1 reference

Lim YL

1

1 reference

16 August 2017

Lee HY

2

1 reference

16 August 2017

Low SC

3

1 reference

16 August 2017

Chan LP

4

1 reference

16 August 2017

Goh NS

5

1 reference

16 August 2017

Pang SM

6

1 reference

16 August 2017

13 April 2007

1 reference

Clinical and Experimental Dermatology

16 August 2017

1 reference

16 August 2017

32

1 reference

16 August 2017

4

1 reference

16 August 2017

353-358

1 reference

Scleromyxoedema-like cutaneous diseases in renal-dialysis patients

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Gadolinium deposition in nephrogenic fibrosing dermopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Safety of approved MR contrast media for intravenous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic fibrosing dermopathy: the first 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2007.02412.X

10.1111/J.1365-2230.2007.02412.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference